A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. BCR, RhoGEF and GTPase activating protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac. Two transcript variants encoding different isoforms have been found for BCR.

The Abbkine Bcr (phospho Tyr177) Rabbit Polyclonal Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and detects endogenous levels of Bcr protein only when phosphorylated at Y177. The antibody has been validaed in WB, ELISA and reacts with Human, Mouse samples.

Abbkine supplies below price/size: $100/30μl, $220/100μl, $360/200μl of Rabbit Anti-Bcr (phospho Tyr177) Polyclonal Antibody at https://www.abbkine.com/product/bcr-phospho-tyr177-polyclonal-antibody-abp50275.

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.